<p>, /PRNewswire/ -- IM Cannabis Corp. (&#34; <strong>IMC</strong>&#34; 或 &#34; <strong>公司</strong>&#34;) (Nasdaq: IMCC) 是一家在以色列和德國運營的醫療大麻公司，今天公佈了截至 2026 年 3 月 31 日的第一季度財務業績。除非另有説明，所有金額均以加元報告。</p>
<p>截至 2026 年 3 月 31 日的三個月內，公司錄得收入 870 萬美元，毛利潤 140 萬美元，營業虧損 170 萬美元，淨虧損 250 萬美元，或每股 0.38 美元。公司還繼續推進成本優化舉措，年度同比減少一般和行政費用 22%。公司還保持對營運資金的嚴格管理和流動性管理，得益於在截至 2026 年 3 月 31 日的季度內完成的可轉換債券融資，以及在季度結束後完成的額外融資。</p>
<p>管理層仍然專注於運營效率、嚴格的營運資金管理，以及持續評估戰略機會以增強公司的長期增長。</p>
<p>完整的中期財務報表和管理層討論與分析可在 SEDAR+ 和 EDGAR 上獲取。</p>
<p><strong>關於 IMC</strong></p>
<p>IMC (Nasdaq: IMCC) 是一家國際公司，專注於在全球市場建立和擴展創新業務和技術。公司目前運營一個醫療大麻平台，為以色列和德國的患者提供服務，同時評估擴展到其他技術驅動行業的機會。</p>
<p>IMC 生態系統通過其子公司在以色列運營，進口和分銷大麻給醫療患者，利用多年的專有數據和患者洞察。公司還在以色列運營醫療大麻零售藥房和在線平台，確保 IMC 產品在整個價值鏈中的安全交付和質量控制。在德國，IMC 生態系統通過 Adjupharm GmbH 運營，向藥房分銷醫療大麻。</p>
<p><strong>前瞻性聲明免責聲明</strong></p>
<p>本新聞稿包含根據適用的加拿大和美國證券法的前瞻性信息或前瞻性聲明（統稱為&#34; <strong>前瞻性聲明</strong>&#34;）。所有涉及我們預計將來發生的活動或發展的信息均視為前瞻性聲明。前瞻性聲明通常但不總是通過使用諸如&#34;尋求&#34;、&#34;預期&#34;、&#34;相信&#34;、&#34;計劃&#34;、&#34;估計&#34;、&#34;期望&#34;、&#34;可能&#34;和&#34;打算&#34;等詞語以及表明某事件或結果&#34;可能&#34;、&#34;將&#34;、&#34;應該&#34;、&#34;可以&#34;或&#34;可能&#34;發生或實現的陳述以及其他類似表達來識別。前瞻性聲明基於管理層在聲明發布之日的估計和意見。在新聞稿中，此類前瞻性聲明包括但不限於與公司的成本優化舉措相關的聲明；公司在 2026 年減少費用的能力；公司的營運資金紀律和流動性管理；未來融資；戰略機會和交易；以及公司在 2026 年的增長。上述前瞻性聲明和假設的列表並不詳盡。由於前瞻性聲明涉及未來事件和條件，其本質上涉及固有的風險和不確定性。實際結果可能與當前預期或前瞻性聲明所暗示的結果有重大差異，原因包括：公司未能遵守高度監管行業的適用法規要求；公司運營所在司法管轄區內政府政策和法規的意外變化；公司繼續滿足納斯達克資本市場上市要求的能力；任何意外未能保持良好信譽或續期其許可證；公司及其子公司（統稱為&#34; <strong>集團</strong>&#34;）履行銷售承諾或增長目標的能力；集團依賴第三方供應協議提供足夠數量的醫療大麻以履行集團的義務；集團可能面臨的責任、相關風險的感知水平，以及涉及集團的任何訴訟或其他類似爭議或法律程序的預期結果；競爭加劇的影響；併購機會的缺乏；不利的市場條件；生產數量、質量和成本估算的固有不確定性及意外成本和費用的潛在風險；產品責任和其他與集團大麻產品使用相關的安全責任風險；供應鏈限制；對關鍵人員的依賴；現有債務違約的風險；東歐和中東地區戰爭、衝突和內亂的風險，包括以色列面臨的多方戰爭對公司、其運營和全球醫療大麻行業的影響；公司專注於以色列和德國市場的風險；公司無法實現可持續盈利和/或增加股東價值的風險；公司無法積極管理成本和/或改善利潤率的風險；公司無法增長和/或維持銷售的風險；公司無法實現其目標和/或戰略計劃的風險；公司無法降低成本和/或維持收入的風險；以及公司無法利用德國醫療大麻合法化的機會。</p>
<p>請參閲公司截至 2025 年 12 月 31 日的年度報告中 “風險因素” 標題下列出的其他風險、不確定性和因素，該報告可在公司在 SEDAR+ 上的發行人資料（www.sedarplus.ca）和 EDGAR（www.sec.gov/edgar）上獲取。本新聞稿中包含的任何前瞻性聲明均基於管理層在作出該前瞻性信息時的信念、估計、預期和意見，並以本新聞稿日期為準。除適用證券法要求外，公司不承擔更新前瞻性聲明的任何義務。投資者不應對前瞻性聲明過度依賴。本新聞稿中包含的前瞻性聲明受到本警示聲明的明確限定。</p>
<p><strong>公司聯繫方式：</strong></p>
<p>Michal Efraty</p>
<p>投資者與公共關係</p>
<p>[email protected]</p>
<p>Oren Shuster，首席執行官</p>
<p>IM Cannabis Corp.</p>
<p>[email protected]</p>
<p>Logo - https://mma.prnewswire.com/media/1742228/5969528/IM_Cannabis_Logo.jpg</p>
<p>來源 IM Cannabis Corp.</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEzJk5ld3NJdGVtSWQ9TE41OTExNyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTMxNjAxUFJfTkVXU19VU1BSX19fX19MTjU5MTE3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEzJk5ld3NJdGVtSWQ9TE41OTExNyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTMxNjAxUFJfTkVXU19VU1BSX19fX19MTjU5MTE3"/></p>

IMCC

<p>IM Cannabis Corp.（納斯達克代碼：IMCC）公佈了 2026 年第一季度的財務業績，報告收入為 870 萬美元，毛利潤為 140 萬美元，淨虧損為 250 萬美元。公司將一般和行政費用同比減少了 22%，並專注於成本優化和流動性管理。IMC 在以色列和德國運營，分銷醫療大麻並評估擴展機會。新聞稿中包含了關於公司未來計劃和潛在風險的前瞻性聲明</p>

<p>, /PRNewswire/ -- IM Cannabis Corp. (&#34; <strong>IMC</strong>&#34; or the &#34; <strong>Company</strong>&#34;) (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, today announced its financial results for the first quarter ended March 31, 2026. All amounts were reported in Canadian dollars, unless otherwise stated.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- IM Cannabis Corp. (&#34; <strong>IMC</strong>&#34; 或 &#34; <strong>公司</strong>&#34;) (Nasdaq: IMCC) 是一家在以色列和德國運營的醫療大麻公司，今天公佈了截至 2026 年 3 月 31 日的第一季度財務業績。除非另有説明，所有金額均以加元報告。</p>
</div><p>For the three months ended March 31, 2026, the Company recorded revenues of $8.7 million, gross profit of $1.4 million, operating loss of $1.7 million, and a net loss of $2.5 million, or $0.38 per share. The Company also continued to advance its cost optimization initiatives, reducing general and administrative expenses by 22% year-over-year. The Company also maintained its focus on working capital discipline and liquidity management, supported by convertible note financings completed during the quarter ended March 31, 2026, and additional financings completed following quarter-end.</p>
<div class="lb-trans"><p>截至 2026 年 3 月 31 日的三個月內，公司錄得收入 870 萬美元，毛利潤 140 萬美元，營業虧損 170 萬美元，淨虧損 250 萬美元，或每股 0.38 美元。公司還繼續推進成本優化舉措，年度同比減少一般和行政費用 22%。公司還保持對營運資金的嚴格管理和流動性管理，得益於在截至 2026 年 3 月 31 日的季度內完成的可轉換債券融資，以及在季度結束後完成的額外融資。</p>
</div><p>Management remains focused on operational efficiencies, disciplined working capital management, and the continued evaluation of strategic opportunities to enhance the Company's long-term growth.</p>
<div class="lb-trans"><p>管理層仍然專注於運營效率、嚴格的營運資金管理，以及持續評估戰略機會以增強公司的長期增長。</p>
</div><p>The full Interim Financial Statements and Management's Discussion and Analysis are available on SEDAR+ and EDGAR.</p>
<div class="lb-trans"><p>完整的中期財務報表和管理層討論與分析可在 SEDAR+ 和 EDGAR 上獲取。</p>
</div><p><strong>About IMC</strong></p>
<div class="lb-trans"><p><strong>關於 IMC</strong></p>
</div><p>IMC (Nasdaq: IMCC) is an international company focused on building and scaling innovative businesses and technologies across global markets. The Company currently operates a medical cannabis platform serving patients in Israel and Germany while evaluating opportunities to expand into additional technology-driven sectors.</p>
<div class="lb-trans"><p>IMC (Nasdaq: IMCC) 是一家國際公司，專注於在全球市場建立和擴展創新業務和技術。公司目前運營一個醫療大麻平台，為以色列和德國的患者提供服務，同時評估擴展到其他技術驅動行業的機會。</p>
</div><p>The IMC ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies and online platforms, in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.</p>
<div class="lb-trans"><p>IMC 生態系統通過其子公司在以色列運營，進口和分銷大麻給醫療患者，利用多年的專有數據和患者洞察。公司還在以色列運營醫療大麻零售藥房和在線平台，確保 IMC 產品在整個價值鏈中的安全交付和質量控制。在德國，IMC 生態系統通過 Adjupharm GmbH 運營，向藥房分銷醫療大麻。</p>
</div><p><strong>Disclaimer for Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明免責聲明</strong></p>
</div><p>This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, &#34; <strong>forward-looking statements</strong>&#34;). All information that addresses activities or developments that we expect to occur in the future is considered forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as &#34;seek&#34;, &#34;anticipate&#34;, &#34;believe&#34;, &#34;plan&#34;, &#34;estimate&#34;, &#34;expect&#34;, &#34;likely&#34; and &#34;intend&#34; and statements that an event or result &#34;may&#34;, &#34;will&#34;, &#34;should&#34;, &#34;could&#34; or &#34;might&#34; occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to the cost optimization initiatives of the Company; the Company's ability to reduce expenses in 2026; the Company's working capital discipline and liquidity management; future financings; strategic opportunities and transactions; and the Company's growth in 2026. . The above list of forward-looking statements and assumptions is not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company's ability to continue to meet the listing requirements of the Nasdaq Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the &#34; <strong>Group</strong>&#34;) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfill the Group's obligations; the Group's possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group's cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the multi front war that Israel is facing on the Company, its operations and the medical cannabis industry in Israel and globally; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the Company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; and the Company's inability to take advantage of the legalization of medicinal cannabis in Germany.</p>
<div class="lb-trans"><p>本新聞稿包含根據適用的加拿大和美國證券法的前瞻性信息或前瞻性聲明（統稱為&#34; <strong>前瞻性聲明</strong>&#34;）。所有涉及我們預計將來發生的活動或發展的信息均視為前瞻性聲明。前瞻性聲明通常但不總是通過使用諸如&#34;尋求&#34;、&#34;預期&#34;、&#34;相信&#34;、&#34;計劃&#34;、&#34;估計&#34;、&#34;期望&#34;、&#34;可能&#34;和&#34;打算&#34;等詞語以及表明某事件或結果&#34;可能&#34;、&#34;將&#34;、&#34;應該&#34;、&#34;可以&#34;或&#34;可能&#34;發生或實現的陳述以及其他類似表達來識別。前瞻性聲明基於管理層在聲明發布之日的估計和意見。在新聞稿中，此類前瞻性聲明包括但不限於與公司的成本優化舉措相關的聲明；公司在 2026 年減少費用的能力；公司的營運資金紀律和流動性管理；未來融資；戰略機會和交易；以及公司在 2026 年的增長。上述前瞻性聲明和假設的列表並不詳盡。由於前瞻性聲明涉及未來事件和條件，其本質上涉及固有的風險和不確定性。實際結果可能與當前預期或前瞻性聲明所暗示的結果有重大差異，原因包括：公司未能遵守高度監管行業的適用法規要求；公司運營所在司法管轄區內政府政策和法規的意外變化；公司繼續滿足納斯達克資本市場上市要求的能力；任何意外未能保持良好信譽或續期其許可證；公司及其子公司（統稱為&#34; <strong>集團</strong>&#34;）履行銷售承諾或增長目標的能力；集團依賴第三方供應協議提供足夠數量的醫療大麻以履行集團的義務；集團可能面臨的責任、相關風險的感知水平，以及涉及集團的任何訴訟或其他類似爭議或法律程序的預期結果；競爭加劇的影響；併購機會的缺乏；不利的市場條件；生產數量、質量和成本估算的固有不確定性及意外成本和費用的潛在風險；產品責任和其他與集團大麻產品使用相關的安全責任風險；供應鏈限制；對關鍵人員的依賴；現有債務違約的風險；東歐和中東地區戰爭、衝突和內亂的風險，包括以色列面臨的多方戰爭對公司、其運營和全球醫療大麻行業的影響；公司專注於以色列和德國市場的風險；公司無法實現可持續盈利和/或增加股東價值的風險；公司無法積極管理成本和/或改善利潤率的風險；公司無法增長和/或維持銷售的風險；公司無法實現其目標和/或戰略計劃的風險；公司無法降低成本和/或維持收入的風險；以及公司無法利用德國醫療大麻合法化的機會。</p>
</div><p>Please see the other risks, uncertainties and factors set out under the heading &#34;Risk Factors&#34; in the Company's annual report for the year ended December 31, 2025, which is available on the Company's issuer profile on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company does not undertake any obligation to update forward-looking statements, except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.</p>
<div class="lb-trans"><p>請參閲公司截至 2025 年 12 月 31 日的年度報告中 “風險因素” 標題下列出的其他風險、不確定性和因素，該報告可在公司在 SEDAR+ 上的發行人資料（www.sedarplus.ca）和 EDGAR（www.sec.gov/edgar）上獲取。本新聞稿中包含的任何前瞻性聲明均基於管理層在作出該前瞻性信息時的信念、估計、預期和意見，並以本新聞稿日期為準。除適用證券法要求外，公司不承擔更新前瞻性聲明的任何義務。投資者不應對前瞻性聲明過度依賴。本新聞稿中包含的前瞻性聲明受到本警示聲明的明確限定。</p>
</div><p><strong>Company Contact:</strong></p>
<div class="lb-trans"><p><strong>公司聯繫方式：</strong></p>
</div><p>Michal Efraty</p>
<div class="lb-trans"><p>Michal Efraty</p>
</div><p>Investor &amp; Public Relations</p>
<div class="lb-trans"><p>投資者與公共關係</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>Oren Shuster, CEO</p>
<div class="lb-trans"><p>Oren Shuster，首席執行官</p>
</div><p>IM Cannabis Corp.</p>
<div class="lb-trans"><p>IM Cannabis Corp.</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>Logo - https://mma.prnewswire.com/media/1742228/5969528/IM_Cannabis_Logo.jpg</p>
<div class="lb-trans"><p>Logo - https://mma.prnewswire.com/media/1742228/5969528/IM_Cannabis_Logo.jpg</p>
</div><p>SOURCE IM Cannabis Corp.</p>
<div class="lb-trans"><p>來源 IM Cannabis Corp.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEzJk5ld3NJdGVtSWQ9TE41OTExNyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTMxNjAxUFJfTkVXU19VU1BSX19fX19MTjU5MTE3" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LN59117&amp;Transmission_Id=202605131601PR_NEWS_USPR_____LN59117&amp;DateId=20260513"/></p>

IM Cannabis 公司宣佈 2026 年第一季度財務業績